Opexa Therapeutics was Downgraded to a Hold Rating at Maxim GroupBy Ryan Adsit
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -9.7% and a 27.5% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Stellar Biotechnologies, and Inovio Pharmaceuticals.
Opexa Therapeutics has an analyst consensus of Hold.
Based on Opexa Therapeutics’ latest earnings report from June 30, the company posted quarterly revenue of $726.3K and quarterly net profit of -$2.1M. In comparison, last year the company earned revenue of $726.3K and had a net profit of -$2.79M.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is negative on the stock. Last month, Timothy Barabe, a a Director at OPXA bought 10,000 shares for a total of $11,500.
Opexa Therapeutics, Inc. engages as a biopharmaceutical company which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. The company was founded in March 1991 and is headquartered in The Woodlands, TX.